Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Effects of maternal iron status on placental and fetal iron homeostasis
Veena Sangkhae, … , Tomas Ganz, Elizabeta Nemeth
Veena Sangkhae, … , Tomas Ganz, Elizabeta Nemeth
Published October 29, 2019
Citation Information: J Clin Invest. 2020;130(2):625-640. https://doi.org/10.1172/JCI127341.
View: Text | PDF
Research Article Hematology Reproductive biology

Effects of maternal iron status on placental and fetal iron homeostasis

  • Text
  • PDF
Abstract

Iron deficiency is common worldwide and is associated with adverse pregnancy outcomes. The increasing prevalence of indiscriminate iron supplementation during pregnancy also raises concerns about the potential adverse effects of iron excess. We examined how maternal iron status affects the delivery of iron to the placenta and fetus. Using mouse models, we documented maternal homeostatic mechanisms that protect the placenta and fetus from maternal iron excess. We determined that under physiological conditions or in iron deficiency, fetal and placental hepcidin did not regulate fetal iron endowment. With maternal iron deficiency, critical transporters mediating placental iron uptake (transferrin receptor 1 [TFR1]) and export (ferroportin [FPN]) were strongly regulated. In mice, not only was TFR1 increased, but FPN was surprisingly decreased to preserve placental iron in the face of fetal iron deficiency. In human placentas from pregnancies with mild iron deficiency, TFR1 was increased, but there was no change in FPN. However, induction of more severe iron deficiency in human trophoblast in vitro resulted in the regulation of both TFR1 and FPN, similar to what was observed in the mouse model. This placental adaptation that prioritizes placental iron is mediated by iron regulatory protein 1 (IRP1) and is important for the maintenance of mitochondrial respiration, thus ultimately protecting the fetus from the potentially dire consequences of generalized placental dysfunction.

Authors

Veena Sangkhae, Allison L. Fisher, Shirley Wong, Mary Dawn Koenig, Lisa Tussing-Humphreys, Alison Chu, Melisa Lelić, Tomas Ganz, Elizabeta Nemeth

×

Figure 7

Iron deficiency impairs oxidative phosphorylation in PHTs.

Options: View larger image (or click on image) Download as PowerPoint
Iron deficiency impairs oxidative phosphorylation in PHTs.
PHTs were tre...
PHTs were treated for 24 hours with 100 μM DFO, apo-Tf, or holo-Tf. (A) Western blotting for OXPHOS complexes CI–CV. β-Actin was used as a loading control. (B) Mitochondrial respiration under basal conditions following injection of oligomycin, the uncoupler FCCP, or the electron transport inhibitors antimycin A and rotenone (AA/ROT). (C) Quantitation of basal respiration, ATP-linked respiration, maximal respiratory capacity, and spare respiratory capacity normalized to total cells per well. Statistical differences between groups were determined by 1-way ANOVA for normally distributed values followed by an all-pairwise multiple comparison (Holm-Sidak method) (###P < 0.001) or 1-way ANOVA on ranks for non-normally distributed values followed by an all-pairwise multiple comparison (Tukey’s test) (#P < 0.05). Lowercase letters indicate a statistical difference compared with DFO (“d”), Apo-Tf (“a”), or Holo-Tf (“h”) group. n = 6 technical replicates. (D) ECAR. (E) Basal OCR versus basal ECAR.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts